Skip to Content
MilliporeSigma
Search Within
Document Type

231-957-4

Applied Filters:
Keyword:'231-957-4'
Showing 1-9 of 9 results for "231-957-4" within Technical Documents
Quality Control Range Sheet- PCC-124 and PCC-224
Corporation, Billerica, MA 01821 USA   GM-CSF Control 1 66 - 137 pg/mL IL-4 Control 1 123 - 255 pg/mL Control 2 461 - 957 pg/mL Control 2 965 - 2004 pg/mL
TB017VM pT7Blue Vector Map
SacI 1 118 SalI 1 63 SapI 1 2663 Sau96I 6 231 499 1294 1516 1533 1612 Sau3AI 12 ScaI 1 1177 ScrFI 10 105 106 164 1122 1473 2169 2387 2400 2521 2809 SfaNI 4 957 1206 1397 2449 SfcI 6 36 57 727 1412
Quality Control Range Sheet- A6602-107 and A6602-207
mL Control 2 95 – 198 pg/mL Control 2 1583 – 3288 pg/mL IL-22 Control 1 461 – 957 pg/mL *RANTES Control 1
ExPlore with Confidence: Prestige Antibodies Breast Cancer Research
ligands are independent predictors of good prognosis in cervical cancer. BMC Cancer 2014 Dec 15; 14:957. Epub 2014 Dec 15. 166. de Kruijf EM et al. NKG2D ligand tumor expression and association with clinical
Cytoskeletal Signaling Antibodies, Reagents and Kits
µL 05-797 (Erk1/2)(Thr185/Tyr187) Anti-MAP Kinase 1/Erk 1, CT M R IPK WB Pur Rb IgG 100 µL 05-957 Polyclonal Antibody Anti-MAP Kinase 1/2 (Erk1/2), CT Av H M R IP WB IC APur Rb IgG 100
XP725 Worksheet for Lot Number 071M4826
IX Myr5 M5566 956 5 4 6 4 Myosin IX Myr5 M5566 957 5 4 6 5 Negative Control NA 958 5 4 6 6 Negative Control NA 959 5 4 6 7 Anti CY3/5 C0992 960 5 4 6 8 Anti CY3/5 C0992 961 6
Halal Certificate
B78093 HC-22SI9A14 956. P,ALPHA,ALPHA-TRIMETHYLBENZYL ALCOHOL 95%, FG W324205 A82307 HC-22SI5T26 957. P,ALPHA-DIMETHYLSTYRENE 98% W314404 A68054 HC-22SIQZ23 958. PALM FRUIT OIL, CERTIFIED ORGANIC (
Halal Certificate
B78093 HC-24SI1C16 956. P,ALPHA,ALPHA-TRIMETHYLBENZYL ALCOHOL 95%, FG W324205 A82307 HC-24SIFG28 957. P,ALPHA-DIMETHYLSTYRENE 98% W314404 A68054 HC-24SIDS25 958. PALM FRUIT OIL, CERTIFIED ORGANIC (
Hallmarks of Cancer - Solutions for life science research
Ibrutinib: a first in class covalent inhibitor of Bruton’s tyrosine kinase. Future Oncol. 2014 May;10(6):957-67. 3. Bertacchini J, et al. Feedbacks and adaptive capabilities of the PI3K/Akt/mTOR axis in